Re-Gro
- Manufacturer
- Empress Hair Products, Ltd. | Contract Pharmaceuticals Limited Canada
- Effective date
- 2014-11-06
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:40:47
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
Active ingredient
Minoxidil, USP 2% w/v
Purpose
Hair regrowth treatment
INDICATIONS & USAGE SECTION
Use to regrow hair on the scalp
Warnings
For external use only
Flammable: Keep away from fire or flame
OTC - DO NOT USE SECTION
Do not use if
- your degree of hair loss is more than that shown on the side of this carton, because this propuct may not work for you
- you have no family history of hair loss
- your hair loss is sudden and/or patchy
- your hair loss is associated with childbirth
- you do not know the reason for your hair loss
- you are under 18 years of age. Do not use on babies and children.
- your scalp is red, inflamed, infected, irritated, or painful
- you use other medicines on the scalp
OTC - ASK DOCTOR SECTION
Ask a doctor before use if you have heart disease
OTC - WHEN USING SECTION
When using this product
- do not apply on other parts of the body
- avoid contact with the eyes. In case of accidental contact, rinse with large amounts of cool tap water.
- some people have experienced changes in hair color and/or texture
- it takes time to regrow hair. You may need to use this product 2 times a day for at least 4 months before you see results.
- the amount of hair regrowth is different for each person. This product will not work for everyone.
OTC - STOP USE SECTION
Stop use and ask a doctor if
- chest pain, rapid heartbeat, faintness, or dizziness occurs
- sudden, unexplained weight gain occurs
- your hands or feet swell
- scalp irritation or redness occurs
- unwanted facial hair growth occurs
- you do not see hair regrowth in 4 months
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
May be harmful if used when pregnant or breast-feeding.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- part your hair and apply with dropper one mL 2 times a day directly onto the scalp in the area of hair thinning/loss
- using more or more often will not improve results
- continued use is necessary to increase and keep your hair regrowth, or hair loss will begin again
Other information
- see hair loss pictures on side of this carton
- before use, read all information on carton and enclosed leaflet
- keep this carton. It contains important information.
- in clinical studies of mostly white women aged 18-45 years with mild to moderate degrees of hair loss, the following response to minoxidil topical solution 2% was reported: 19% of women reported moderate hair regrowth after using minoxidil topical solution 2% for 8 months (19% had moderate regrowth; 40% had minimal regrowth). This compares with 7% of women reporting moderate hair regrowth after using the placebo, the liquid without minoxidil in it, for 8 months (7% had moderate regrowth; 33% had minimal regrowth).
- store at controlled room temperature 20° to 25°C (68° to 77°F). Keep tightly closed.
INACTIVE INGREDIENT SECTION
Inactive ingredients alcohol (60% v/v), propylene glycol, purified water
OTC - QUESTIONS SECTION
Questions? 1-800-432-8534 between 9 am and 4 pm EST, Monday-Friday.
———Package Label.Principal Display Panel———
NDC 60900-555-30
Compare to the active ingredient
in Women's Rogaine®*
EMPRESS®
Re-Gro™ Hair Products for Women of Color
Hair Regrowth
Treatment
Minoxidil Topical
Solution,
USP 2%
FOR WOMEN
Unscented
Clinically Proven to
Help Regrow Hair
Revitalized Hair Follicles
Three Month Supply
3-60 mL (2 fl oz) Bottles

DailyMed RxNorm Mappings#
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| MINOXIDIL Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60900-555-10 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-bd31-f424-e053-dadaa90a57ce | f7d77d71-566f-4b9f-90a7-7a4ae82f567f |
| 60900-555-20 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-bd31-f424-e053-dadaa90a57ce | f7d77d71-566f-4b9f-90a7-7a4ae82f567f |
| 60900-555-30 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-bd31-f424-e053-dadaa90a57ce | f7d77d71-566f-4b9f-90a7-7a4ae82f567f |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60900-555-10 | Re-Gro | 1 in 1 CARTON | SOLUTION | 1 | 1 | |
| 60900-555-10 | Re-Gro | 60 mL in 1 BOTTLE | SOLUTION | 60 | 1 | |
| 60900-555-20 | Re-Gro | 60 mL in 1 BOTTLE | SOLUTION | 60 | 1 | |
| 60900-555-20 | Re-Gro | 2 in 1 CARTON | SOLUTION | 2 | 1 | |
| 60900-555-30 | Re-Gro | 60 mL in 1 BOTTLE | SOLUTION | 60 | 1 | |
| 60900-555-30 | Re-Gro | 3 in 1 CARTON | SOLUTION | 3 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| MINOXIDIL | ACTIVE INGREDIENT | 5965120SH1 | 1 | |
| MINOXIDIL | ACTIVE MOIETY | 5965120SH1 | 1 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- Re-Gro
- minoxidil
- ALCOHOL
- PROPYLENE GLYCOL
- WATER
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 60900-555 | 60900-555-10, 60900-555-20, 60900-555-30 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MINOXIDIL | 5965120SH1 | ACTIB |
| ALCOHOL | 3K9958V90M | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAMUSCULAR | 4000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAMUSCULAR | 1491 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / ORAL | 681 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / SUBLINGUAL | 36 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | PASTE / DENTAL | 0.5 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY, METERED / SUBLINGUAL | 29 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TRANSDERMAL | 90 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / VAGINAL | 750 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, METERED / RECTAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | ELIXIR / ORAL | 9306 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAMUSCULAR | 7459 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TRANSDERMAL | 3675 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / TOPICAL | 4886 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / NASAL | 10 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / NASAL | 20 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TRANSDERMAL | 7360 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE / ORAL | 1072 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / RESPIRATORY (INHALATION) | 25 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / AURICULAR (OTIC) | 56.55 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TOPICAL | 541 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / ORAL | 150.68 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / VAGINAL | 1225 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO / TOPICAL | 8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / NASAL | 70 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / RESPIRATORY (INHALATION) | 0.08 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAMUSCULAR | 400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / RESPIRATORY (INHALATION) | 10 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / OPHTHALMIC | 1.5 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SWAB / TOPICAL | 2250 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SYRUP / ORAL | 21000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / SUBCUTANEOUS | 149 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, COATED / ORAL | 16 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 35.75 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, EXTENDED RELEASE / TRANSDERMAL | 58.13 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / ORAL | 29008 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / OPHTHALMIC | 0.6 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v |
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074588-001 | MINOXIDIL (FOR MEN) | MINOXIDIL | 2% | SOLUTION / TOPICAL | 1996-04-05 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074588-001 | MINOXIDIL (FOR MEN) | 2% | SOLUTION / TOPICAL | 1996-04-05 | 3a93d1ddd44b… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 1fc33789-c0fc-4aa9-b865-2690af27f544 | f7d77d71-566f-4b9f-90a7-7a4ae82f567f | 2014-11-06 | Warnings | 1fc33789-c0fc-4aa9-b865-2690af27f544 f7d77d71-566f-4b9f-90a7-7a4ae82f567f |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.